Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03794583 · ClinicalTrials.gov registry record · Phase 3
Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
A Phase 3 study, sponsored by United Therapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 41
- Enrollment target
NCT03794583 is a Phase 3 study that was terminated before completion, run by United Therapeutics. The registered enrollment target is 41 participants.
The verdict
NCT03794583, a Phase 3 study, was terminated before completion, sponsored by United Therapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 41 participants
- Enrollment target
Study Summary
This open-label study will evaluate the safety of continued therapy with inhaled treprostinil in participants who have completed Study RIN-PH-304 (NCT03496623). This study hypothesizes that long-term safety findings will be similar to those observed in the randomized, placebo-controlled, double-blind, adaptive study 'A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients with Pulmonary Hypertension due to Chronic Obstructive Pulmonary Disease (PH-COPD)(RIN-PH-304).
Interventions
- DRUG Inhaled treprostinil solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2018-12-21 |
| Est. Completion | 2022-11-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03794583
The ClinicalTrials.gov registry entry for NCT03794583 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is United Therapeutics, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Inhaled treprostinil solution is the first listed.
NCT03794583 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03794583 about?
NCT03794583 is a clinical study titled "Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)". This open-label study will evaluate the safety of continued therapy with inhaled treprostinil in participants who have completed Study RIN-PH-304 (NCT03496623). This study hypothesizes that long-term safety findings will be similar to those observed in the randomized, placebo-controlled, double-blin...
What is the current status of trial NCT03794583?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 41 participants. The study started on 2018-12-21. Estimated completion is 2022-11-29.
What interventions are being tested in trial NCT03794583?
The interventions under investigation include: Inhaled treprostinil solution (DRUG).
Who is sponsoring clinical trial NCT03794583?
This trial is sponsored by United Therapeutics, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.